Literature DB >> 16477107

Return to work still possible after several years as a disability pensioner due to musculoskeletal disorders: a population-based study after new legislation in Sweden permitting "resting disability pension".

Lena Edén1, Ingemar H Andersson, Göran Ejlertsson, Britt Inger Ekström, Yvonne Johansson, Ido Leden, Jan Petersson.   

Abstract

Different strategies have been used to stimulate a return to work (RTW) among individuals suffering from long-term ailments. In Sweden a new law on "resting disability pension" permits disability pensioners to go back to work without jeopardising their benefits. In this study different variables related to RTW during 2000 by means of this legislation were identified among disability pensioners with musculoskeletal disorders. Individuals in the study group, when compared to a control group, had more often been disability pensioners for several years, had additional education, estimated their previous job to have been physically strenuous to a lesser degree, were more satisfied with the treatment at the social insurance office and had a more positive self-image. This study shows that it may be meaningful to continue/resume rehabilitation efforts and to try to motivate an individual suffering from musculoskeletal disorders to return to work even after several years as a disability pensioner.

Entities:  

Mesh:

Year:  2006        PMID: 16477107

Source DB:  PubMed          Journal:  Work        ISSN: 1051-9815


  2 in total

1.  Disability, sickness, and unemployment benefits among long-term sickness absentees five years before, during, and after a multidisciplinary medical assessment.

Authors:  Klas Gustafsson; Göran Lundh; Pia Svedberg; Jürgen Linder; Kristina Alexanderson; Staffan Marklund
Journal:  J Multidiscip Healthc       Date:  2011-03-11

2.  Long-term follow-up of disability pensioners having musculoskeletal disorders.

Authors:  Liv H Magnussen; Liv I Strand; Jan S Skouen; Hege R Eriksen
Journal:  BMC Public Health       Date:  2009-11-10       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.